Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Richter

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Blood Cancer Journal|April 12, 2024
Like a bridge over troubled water: keeping the myeloma down en route to CAR-TJoshua Richter
Expert Review of Hematology|March 19, 2026
An interview with dr. Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (commissioning Editor)Joshua Richter
British Journal of Haematology|December 19, 2023
T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails!Joshua Richter
Frontiers in Oncology|February 7, 2022
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and PipedreamsDarren Pan, Joshua Richter
Cancer Journal (Sudbury, Mass.)|January 30, 2019
Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage TherapiesJoshua Richter, Sundar Jagannath
Blood Reviews|January 1, 2021
Anti-body building: The exercise of advancing immune based myeloma therapiesJoshua Richter, Santiago Thibaud
Current Hematologic Malignancy Reports|August 15, 2024
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple MyelomaDarren Pan, Joshua Richter
Blood|October 20, 2018
Walking on myelomaBart Barlogie, Joshua Richter
Clinical Lymphoma, Myeloma & Leukemia|October 6, 2018
Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple MyelomaJoshua Richter, Sundar Jagannath
Cancer Management and Research|July 27, 2023
Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific AntibodyDarren Pan, Joshua Richter
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Blood Cancer Journal|April 12, 2024
Like a bridge over troubled water: keeping the myeloma down en route to CAR-TJoshua Richter
Expert Review of Hematology|March 19, 2026
An interview with dr. Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (commissioning Editor)Joshua Richter
British Journal of Haematology|December 19, 2023
T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails!Joshua Richter
Frontiers in Oncology|February 7, 2022
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and PipedreamsDarren Pan, Joshua Richter
Cancer Journal (Sudbury, Mass.)|January 30, 2019
Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage TherapiesJoshua Richter, Sundar Jagannath
Blood Reviews|January 1, 2021
Anti-body building: The exercise of advancing immune based myeloma therapiesJoshua Richter, Santiago Thibaud
Current Hematologic Malignancy Reports|August 15, 2024
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple MyelomaDarren Pan, Joshua Richter
Blood|October 20, 2018
Walking on myelomaBart Barlogie, Joshua Richter
Clinical Lymphoma, Myeloma & Leukemia|October 6, 2018
Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple MyelomaJoshua Richter, Sundar Jagannath
Cancer Management and Research|July 27, 2023
Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific AntibodyDarren Pan, Joshua Richter
Pageof 13